These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 35214655)

  • 21. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
    Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
    Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A conjoined universal helper epitope can unveil antitumor effects of a neoantigen vaccine targeting an MHC class I-restricted neoepitope.
    Swartz AM; Congdon KL; Nair SK; Li QJ; Herndon JE; Suryadevara CM; Riccione KA; Archer GE; Norberg PK; Sanchez-Perez LA; Sampson JH
    NPJ Vaccines; 2021 Jan; 6(1):12. PubMed ID: 33462231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
    Chen H; Yang G; Xiao J; Zheng L; You L; Zhang T
    Cancer Lett; 2020 Oct; 490():12-19. PubMed ID: 32590021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives.
    Chen X; Yang J; Wang L; Liu B
    Theranostics; 2020; 10(13):6011-6023. PubMed ID: 32483434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor neoantigens: from basic research to clinical applications.
    Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
    J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Role of Neoantigens in Cancer Immunotherapy.
    Zhu Y; Liu J
    Front Oncol; 2021; 11():682325. PubMed ID: 34513673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Personalized cancer neoantigen vaccines come of age.
    Chu Y; Liu Q; Wei J; Liu B
    Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roadmap to next-generation cancer vaccines.
    Zheng Y; Zhong Z
    J Control Release; 2022 Jul; 347():308-313. PubMed ID: 35561869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Advances in Cancer Immunotherapy with a Focus on FDA-Approved Vaccines and Neoantigen-Based Vaccines.
    Hargrave A; Mustafa AS; Hanif A; Tunio JH; Hanif SNM
    Vaccines (Basel); 2023 Oct; 11(11):. PubMed ID: 38005965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoantigen: A New Breakthrough in Tumor Immunotherapy.
    Zhang Z; Lu M; Qin Y; Gao W; Tao L; Su W; Zhong J
    Front Immunol; 2021; 12():672356. PubMed ID: 33936118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small-scale manufacturing of neoantigen-encoding messenger RNA for early-phase clinical trials.
    Ingels J; De Cock L; Mayer RL; Devreker P; Weening K; Heyns K; Lootens N; De Smet S; Brusseel M; De Munter S; Pille M; Billiet L; Goetgeluk G; Bonte S; Jansen H; Lint SV; Leclercq G; Taghon T; Menten B; Vermaelen K; Impens F; Vandekerckhove B
    Cytotherapy; 2022 Feb; 24(2):213-222. PubMed ID: 34696961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biotechnologies to tackle the challenge of neoantigen identification.
    Arnaud M; Duchamp M; Bobisse S; Renaud P; Coukos G; Harari A
    Curr Opin Biotechnol; 2020 Oct; 65():52-59. PubMed ID: 31927304
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Current Lung Cancer Neoantigen Landscape and Implications for Therapy.
    Ye L; Creaney J; Redwood A; Robinson B
    J Thorac Oncol; 2021 Jun; 16(6):922-932. PubMed ID: 33581342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
    Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
    Front Immunol; 2021; 12():691605. PubMed ID: 34484187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoantigen Vaccines; Clinical Trials, Classes, Indications, Adjuvants and Combinatorial Treatments.
    Niemi JVL; Sokolov AV; Schiöth HB
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoantigen vaccine: An emerging immunotherapy for hepatocellular carcinoma.
    Chen P; Fang QX; Chen DB; Chen HS
    World J Gastrointest Oncol; 2021 Jul; 13(7):673-683. PubMed ID: 34322196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.